Pricing drugs, selling hype and how we got here in the first place
May 15, 2018 - 15:46
Radio and PodcastLive Radio & Podcasts
Science & Medicine
GSK's CEO shakeup, Lilly's Alzheimer's uncertainty, and Valeant's latest disaster
Fierce editors discuss the pending retirement of GlaxoSmithKline CEO Andrew Witty, Eli Lilly's bold decision with a big Alzheimer's trial and Valeant Pharmaceuticals' rough week.
Related Episodes
Continue listening to more episodes from FierceBiotech Radio.
